How much revenue does Sun Pharmaceutical Industries make?

Sun Pharmaceutical Industries reported 582.20 billion INR in revenue for fiscal year 2026, up 11.9% from 520.41 billion INR in fiscal year 2025. In Q1 2027 revenue was 151.84 billion INR.

Where does Sun Pharmaceutical Industries make most of its revenue?

India: 33% of revenue by region in fiscal year 2025, followed by United States of America (33%).

What companies are similar to Sun Pharmaceutical Industries?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Torrent Pharmaceuticals Limited (TORNTPHARM.NS), Zydus Lifesciences Limited (ZYDUSLIFE.NS), Cipla Limited (CIPLA.NS), Mankind Pharma Limited (MANKIND.NS).

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) Stock

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, opht...

At a glance

Sun Pharmaceutical Industries reported revenue of 582.20 billion INR for fiscal year 2026, up 11.9% from fiscal year 2025, and net income of 114.79 billion INR. In Q1 2027 (the quarter ended June 30, 2026) revenue was 151.84 billion INR, up 10.1% from a year before. India was its largest region in fiscal year 2025, with 33% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2026.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.